Develops cancer medicines, including firmonertinib for patients with uncommon lung-cancer mutations and antibody-drug conjugates for people with solid tumors.
10-K for FY2025, filed Mar 5, 2026
8-K, filed Nov 9, 2026
Reported Phase 3 FURVENT Results and Evaluating Next Steps. FURVENT did not meet its primary endpoint of progression-free survival (PFS) by…View ↗
8-K, filed Aug 12, 2026
On August 11, 2026, ArriVent BioPharma, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Allist License…View ↗
Competes with AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Cullinan Therapeutics, Taiho Pharmaceutical, Boehringer Ingelheim, and Bayer
10-K for FY2025, filed Mar 5, 2026Companies that compete with us directly on the level of commercialization or development of product candidates targeting EGFR…View ↗
Loading...